Trajan Wealth LLC Acquires 12,346 Shares of Cencora, Inc. $COR

Trajan Wealth LLC raised its holdings in shares of Cencora, Inc. (NYSE:COR) by 10.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 135,306 shares of the company’s stock after purchasing an additional 12,346 shares during the quarter. Cencora accounts for about 1.8% of Trajan Wealth LLC’s portfolio, making the stock its 12th largest position. Trajan Wealth LLC’s holdings in Cencora were worth $42,287,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Norges Bank bought a new position in shares of Cencora in the 2nd quarter valued at about $695,215,000. Mizuho Markets Americas LLC increased its stake in Cencora by 116.4% during the third quarter. Mizuho Markets Americas LLC now owns 212,800 shares of the company’s stock worth $66,506,000 after acquiring an additional 1,511,906 shares during the last quarter. Artisan Partners Limited Partnership purchased a new stake in Cencora during the second quarter valued at approximately $411,888,000. Vanguard Group Inc. lifted its stake in shares of Cencora by 5.3% in the 2nd quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock valued at $6,740,340,000 after purchasing an additional 1,125,661 shares during the last quarter. Finally, Viking Global Investors LP lifted its stake in shares of Cencora by 95.0% in the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after purchasing an additional 1,013,913 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

COR has been the subject of a number of analyst reports. Robert W. Baird set a $415.00 price target on Cencora in a research report on Tuesday, January 13th. Barclays upped their price target on shares of Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a report on Friday, February 13th. JPMorgan Chase & Co. increased their price objective on shares of Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. Evercore dropped their target price on Cencora from $440.00 to $420.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Finally, TD Cowen upped their target price on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $399.00.

Insider Transactions at Cencora

In related news, CEO Robert P. Mauch sold 5,096 shares of the firm’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the completion of the transaction, the chief executive officer owned 66,726 shares of the company’s stock, valued at $23,669,713.98. This trade represents a 7.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Silvana Battaglia sold 1,677 shares of the company’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $345.00, for a total transaction of $578,565.00. Following the completion of the sale, the executive vice president directly owned 18,796 shares in the company, valued at approximately $6,484,620. The trade was a 8.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 15,220 shares of company stock worth $5,282,867 over the last 90 days. 0.38% of the stock is currently owned by company insiders.

Cencora Trading Up 0.4%

Cencora stock opened at $360.70 on Monday. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92. The stock has a market cap of $70.17 billion, a PE ratio of 43.35, a price-to-earnings-growth ratio of 1.68 and a beta of 0.68. The stock has a 50-day moving average of $349.41 and a two-hundred day moving average of $331.39. Cencora, Inc. has a one year low of $240.72 and a one year high of $377.54.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.04 by $0.04. The business had revenue of $85.93 billion for the quarter, compared to analyst estimates of $86.12 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. Cencora’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.73 EPS. On average, research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Stockholders of record on Friday, February 13th will be issued a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Cencora’s dividend payout ratio is 28.85%.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.